Featured Research

from universities, journals, and other organizations

Potential new use found for cancer drug in gene therapy for blood disorders

Date:
June 26, 2014
Source:
Scripps Research Institute
Summary:
Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell’s natural defenses and efficiently insert disease-fighting genes into the cell’s genome. These findings could lead to more effective and affordable long-term treatments for blood cell disorders in which mutations in the DNA cause abnormal cell functions, such as in leukemia and sickle cell anemia.

Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell's natural defenses and efficiently insert disease-fighting genes into the cell's genome.

In a new study led by Associate Professor Bruce Torbett at The Scripps Research Institute (TSRI), a team of researchers report that the drug rapamycin, which is commonly used to slow cancer growth and prevent organ rejection, enables delivery of a therapeutic dose of genes to blood stem cells while preserving stem cell function.

These findings, published recently online ahead of print by the journal Blood, could lead to more effective and affordable long-term treatments for blood cell disorders in which mutations in the DNA cause abnormal cell functions, such as in leukemia and sickle cell anemia.

Improving Gene Delivery to Blood Stem Cells

Viruses infect the body by inserting their own genetic material into human cells. In gene therapy, however, scientists have developed "gutted" viruses, such as the human immunodeficiency virus (HIV), to produce what are called "viral vectors." Viral vectors carry therapeutic genes into cells without causing viral disease. Torbett and other scientists have shown that HIV vectors can deliver genes to blood stem cells.

For a disease such as leukemia or leukodystrophy, where mutations in the DNA cause abnormal cell function, efficiently targeting the stem cells that produce these blood cells could be a successful approach to halting the disease and prompting the body to produce healthy blood cells.

"If you produce a genetic modification in your blood stem cells when you are five years old, these changes are lifelong," said Torbett. Furthermore, the gene-modified stem cells can develop into many types of cells that travel throughout the body to provide therapeutic effects.

However, because cells have adapted defense mechanisms to overcome disease-causing viruses, engineered viral vectors can be prevented from efficiently delivering genes. Torbett said that when scientists extract blood stem cells from the body for gene therapy, HIV viral vectors are usually able to deliver genes to only 30 to 40 percent of them. For leukemia, leukodystrophy or genetic diseases where treatment requires a reasonable number of healthy cells coming from stem cells, this number may be too low for therapeutic purposes.

This limitation prompted Torbett and his team, including TSRI graduate student Cathy Wang, the first author of the study, to test whether rapamycin could improve delivery of a gene to blood stem cells. Rapamycin was selected for evaluation based on its ability to control virus entry and slow cell growth.

The researchers began by isolating stem cells from cord blood samples. They exposed the blood stem cells to rapamycin and HIV vectors engineered to deliver a gene for a green florescent protein, which causes cells to glow. This fluorescence provided a visual marker that helped the researchers track gene delivery.

The researchers saw a big difference in both mouse and human stem cells treated with rapamycin, where therapeutic genes were inserted into up to 80 percent of cells. This property had never been connected to rapamycin before.

Helping Blood Stem Cells Survive

The researchers also found that rapamycin can keep stem cells from differentiating as quickly when taken out of the body for gene therapy. This is important because scientists need time to work on extracted blood stem cells -- yet once these cells leave the body, they begin to differentiate if manipulated into other types of blood cells and lose the ability to remain as stem cells and pass on therapeutic genes.

"We wanted to make sure the conditions we will use preserve stem cells, so if we transplant them back into our animal models, they act just like the original stem cells," said Torbett. "We showed that in two sets of animal models, stem cells remain and produce gene-modified cells."

The researchers hope these methods could someday be useful in the clinic. "Our methods could reduce costs and the amount of preparation that goes into modifying blood stem cells using viral vector gene therapy," said Wang. "It would make gene therapy accessible to a lot more patients."

She said the next steps are to carry out preclinical studies using rapamycin with stem cells in other animal models and then see if the method is safe and effective in humans. The team is also working to delineate the dual pathways of rapamycin's method of action in blood stem cells.


Story Source:

The above story is based on materials provided by Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. X. Wang, B. D. Sather, X. Wang, J. Adair, I. Khan, S. Singh, S. Lang, A. Adams, G. Curinga, H.-P. Kiem, C. H. Miao, D. J. Rawlings, B. E. Torbett. Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood, 2014; DOI: 10.1182/blood-2013-12-546218

Cite This Page:

Scripps Research Institute. "Potential new use found for cancer drug in gene therapy for blood disorders." ScienceDaily. ScienceDaily, 26 June 2014. <www.sciencedaily.com/releases/2014/06/140626160845.htm>.
Scripps Research Institute. (2014, June 26). Potential new use found for cancer drug in gene therapy for blood disorders. ScienceDaily. Retrieved September 30, 2014 from www.sciencedaily.com/releases/2014/06/140626160845.htm
Scripps Research Institute. "Potential new use found for cancer drug in gene therapy for blood disorders." ScienceDaily. www.sciencedaily.com/releases/2014/06/140626160845.htm (accessed September 30, 2014).

Share This



More Health & Medicine News

Tuesday, September 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins